Previous 10 | Next 10 |
Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on August 17 due to it failing to meet its primary endpoint in Unity’s ongoing Phas...
Unity Biotechnology (UBX): Q3 GAAP EPS of -$0.52 misses by $0.10.Cash, cash equivalents and marketable securities of $132.2M.“Over the past quarter we have focused our resources on cellular senescence programs in ophthalmology and neurology. Building on the strong foundation of ou...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020. &...
Unity Biotechnology ([[UBX]] +8.3%) has dosed the first patient in a Phase 1 study of UBX1325 in patients with diabetic macular edema ((DME)).The single-ascending dose, 15-subject study will evaluate the safety, tolerability and pharmacokinetics of UBX1325, with data expected in 1H of 20...
SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that the first patient has been dosed in a Phas...
The following slide deck was published by Unity Biotechnology, Inc. in conjunction with this Read more ...
Putting Together Your List Of Penny Stocks To Watch? Do you like biotech penny stocks ? You’re likely among a unique group of investors that can handle risk. When it comes to these cheap stocks, not only does volatility play a role, so does speculation. Most small-cap biotech stocks ...
Unity Biotechnology ( UBX +10.4% ) has announced to cut its workforce by ~30% to align resources on cellular senescence programs in ophthalmology and neurology and extend operating capital. More news on: Unity Biotechnology, Inc., Healthcare stocks news, Stocks on the move, Read mo...
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX],...
SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team wil...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been e...